Daxor (DXR) Competitors $7.38 -0.07 (-0.94%) As of 04/30/2025 10:52 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DXR vs. SGHT, ZJYL, PROF, AVR, LUCD, KRMD, SKIN, OBIO, INFU, and MGRMShould you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Sight Sciences (SGHT), Jin Medical International (ZJYL), Profound Medical (PROF), Anteris Technologies Global (AVR), Lucid Diagnostics (LUCD), KORU Medical Systems (KRMD), Beauty Health (SKIN), Orchestra BioMed (OBIO), InfuSystem (INFU), and Monogram Orthopaedics (MGRM). These companies are all part of the "medical equipment" industry. Daxor vs. Sight Sciences Jin Medical International Profound Medical Anteris Technologies Global Lucid Diagnostics KORU Medical Systems Beauty Health Orchestra BioMed InfuSystem Monogram Orthopaedics Sight Sciences (NASDAQ:SGHT) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Does the media refer more to SGHT or DXR? In the previous week, Sight Sciences had 6 more articles in the media than Daxor. MarketBeat recorded 7 mentions for Sight Sciences and 1 mentions for Daxor. Daxor's average media sentiment score of 0.93 beat Sight Sciences' score of 0.70 indicating that Daxor is being referred to more favorably in the news media. Company Overall Sentiment Sight Sciences Positive Daxor Positive Do analysts rate SGHT or DXR? Sight Sciences presently has a consensus target price of $3.83, indicating a potential upside of 25.68%. Daxor has a consensus target price of $25.00, indicating a potential upside of 238.75%. Given Daxor's stronger consensus rating and higher probable upside, analysts plainly believe Daxor is more favorable than Sight Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sight Sciences 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer SGHT or DXR? Sight Sciences received 18 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 29.85% of users gave Sight Sciences an outperform vote. CompanyUnderperformOutperformSight SciencesOutperform Votes2029.85% Underperform Votes4770.15% DaxorOutperform Votes2100.00% Underperform VotesNo Votes Do insiders and institutionals hold more shares of SGHT or DXR? 55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 28.9% of Sight Sciences shares are held by company insiders. Comparatively, 59.0% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, SGHT or DXR? Daxor has lower revenue, but higher earnings than Sight Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSight Sciences$79.87M1.97-$55.55M-$1.03-2.96Daxor$2.13M16.75N/AN/AN/A Which has more risk & volatility, SGHT or DXR? Sight Sciences has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Is SGHT or DXR more profitable? Daxor has a net margin of 0.00% compared to Sight Sciences' net margin of -63.30%. Daxor's return on equity of 0.00% beat Sight Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Sight Sciences-63.30% -47.28% -32.72% Daxor N/A N/A N/A SummaryDaxor beats Sight Sciences on 9 of the 15 factors compared between the two stocks. Get Daxor News Delivered to You Automatically Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXR vs. The Competition Export to ExcelMetricDaxorSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.70M$4.39B$5.57B$7.83BDividend YieldN/A39.98%5.11%4.22%P/E RatioN/A30.6722.4418.48Price / Sales16.7554.91394.09103.59Price / CashN/A51.0838.1834.62Price / BookN/A6.116.774.25Net IncomeN/A$68.15M$3.22B$248.23M7 Day Performance-5.02%-0.12%1.49%0.89%1 Month Performance-9.34%-2.24%4.00%3.53%1 Year Performance-24.69%24.15%16.21%5.08% Daxor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRDaxor3.9917 of 5 stars$7.38-0.9%$25.00+238.8%-23.8%$35.70M$2.13M0.0037Gap UpSGHTSight Sciences3.6845 of 5 stars$2.86+3.7%$3.83+33.9%-45.0%$146.97M$79.87M-2.81210ZJYLJin Medical InternationalN/A$0.91+2.5%N/A-76.1%$142.61M$23.50M0.00245PROFProfound Medical2.2439 of 5 stars$4.64+1.6%$14.25+207.4%-32.9%$139.24M$10.68M-3.46150Upcoming EarningsAVRAnteris Technologies GlobalN/A$3.37+7.3%$16.50+389.6%N/A$121.40M$2.71M0.00138News CoveragePositive NewsLUCDLucid Diagnostics2.4989 of 5 stars$1.29+7.1%$3.50+172.4%+38.7%$116.62M$4.35M-1.1370KRMDKORU Medical Systems3.2534 of 5 stars$2.45+9.2%$4.70+92.2%+26.7%$112.37M$33.65M-9.7880Upcoming EarningsNews CoveragePositive NewsGap DownSKINBeauty Health1.9888 of 5 stars$0.88+7.3%$2.50+183.8%-69.3%$110.34M$334.29M-2.101,030Upcoming EarningsGap DownOBIOOrchestra BioMed2.7558 of 5 stars$2.84flat$15.00+428.2%-32.7%$108.62M$2.64M-1.764Gap UpHigh Trading VolumeINFUInfuSystem1.49 of 5 stars$4.80-2.2%$13.00+170.8%-37.2%$100.88M$134.86M80.01410Positive NewsMGRMMonogram Orthopaedics2.453 of 5 stars$2.63-0.8%$5.40+105.3%+47.7%$92.70M$364,999.00-5.5928Gap Up Related Companies and Tools Related Companies Sight Sciences Alternatives Jin Medical International Alternatives Profound Medical Alternatives Anteris Technologies Global Alternatives Lucid Diagnostics Alternatives KORU Medical Systems Alternatives Beauty Health Alternatives Orchestra BioMed Alternatives InfuSystem Alternatives Monogram Orthopaedics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DXR Stock Free DXR Stock Alerts